EXEL

Exelixis Inc

58.39

Oct 02 • 3:59 PM ET +0.45 (0.78%)

57.53

Aftermarket • 7:35 PM ET -0.86 (-1.47%)

Healthcare Biotechnology USA Large NASD

Peers: INCY JAZZ BMRN ALNY IONS RARE MRNA NBIX REGN VRTX

| Held by: IJH VTI VB XMHQ VBK VXF XBI MDY IBB FBT

Scroll to Statements

Index	-
Market Cap	14.47B
Enterprise Value	13.79B
Income	860.62M
Sales	2.44B
Book/sh	7.41
Cash/sh	3.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1077
IPO	Apr 11, 2000

P/E	18.34
Forward P/E	14.12
PEG	0.76
P/S	5.94
P/B	7.88
P/C	17.24
P/FCF	12.34
EV/EBITDA	13.52
EV/Sales	5.66
Quick Ratio	3.38
Current Ratio	3.46
Debt/Eq	0.09
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	3.18
EPS next Y	4.13
EPS next Q	0.88
EPS this Y	14.04%
EPS next Y	17.71%
EPS next 5Y	18.47%
EPS past 3/5Y	70.35% 51.19%
Sales past 3/5Y	12.93% 18.63%
EPS Y/Y TTM	53.08%
Sales Y/Y TTM	9.23%
EPS Q/Q	25.63%
Sales Q/Q	10.63%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	6.63% -1.21%

Insider Own	3.18%
Insider Trans	-2.82%
Inst Own	105.71%
Inst Trans	-1.34%
ROA	33.28%
ROE	44.39%
ROIC	42.82%
Gross Margin	96.48%
Oper. Margin	40.72%
Profit Margin	35.33%
SMA20	1.08%
SMA50	4.58%
SMA200	18.98%
Trades

Shs Outstand	248.88M
Shs Float	239.91M
Short Float	11.00%
Short Ratio	11.17
Short Interest	26.40M
52W High	61.14 -4.50%
52W Low	33.76 72.98%
Volatility	2.77% 2.73%
ATR (14)	1.63
RSI (14)	56.13
Beta	0.48
Rel Volume	0.83
Avg Volume	2.36M
Volume	1,969,279

Perf Week	0.40%
Perf Month	-0.24%
Perf Quarter	5.15%
Perf Half Y	33.07%
Perf YTD	33.22%
Perf Year	41.21%
Perf 3Y	162.78%
Perf 5Y	171.08%
Perf 10Y	356.53%
Recom	2.40
Target Price	53.93
Prev Close	57.94
Price	58.39
Change %	0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-26	Initiated	BMO Capital Markets	Market Perform	$54
Aug-06-26	Downgrade	Leerink Partners	Outperform → Market Perform	$52
Jun-25-26	Resumed	Truist	Hold	$54
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$48
Jan-05-26	Downgrade	BofA Securities	Neutral → Underperform	$41
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-21-25	Upgrade	Leerink Partners	Market Perform → Outperform	$48
Sep-19-25	Resumed	Barclays	Equal Weight	$40
Sep-17-25	Resumed	Barclays	Equal Weight	$40
Sep-17-25	Initiated	Goldman	Buy	$47
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$45 → $50
Jun-24-25	Upgrade	Stephens	Equal-Weight → Overweight	$60
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$36
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$30 → $40
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$36 → $40
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral	$35 → $39
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30

Show Previous Ratings

Sep-30-26 03:43PM	Exelixis Shares Rising on CABOMETYX Revenue (FX Empire)
Sep-11-26 04:19PM	EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review William Blair Sees More Swings In Near Term (Stocktwits)
10:10AM	Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay (Investor's Business Daily)
09:30AM	Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months (InvestorsHub)
Sep-04-26 12:56PM	IBD Stock Of The Day Exelixis Hits Earnings Snag - And Then Breaks Out (Investor's Business Daily)
01:31PM	Loading…
Sep-02-26 01:31PM	Cancer Stock Breaks Out To Highs; Key FDA Action On Watch (Investor's Business Daily)
Sep-01-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September (Business Wire)
Aug-31-26 02:30PM	Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories (Business Wire)
Aug-28-26 11:23AM	Strong Sales, Earnings Send Exelixis Shares Higher (FX Empire)
Aug-24-26 02:36PM	Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition (Trefis)
Aug-21-26 07:14PM	Exelixis, Valaris, and 3 More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-26 04:14PM	Why This Top-Ranked IBD 50 Stock Just Tumbled On Its Earnings (Investor's Business Daily) -7.94%
01:04AM	Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ... (GuruFocus.com)
Aug-05-26 04:35PM	Exelixis: Q2 Earnings Snapshot (Associated Press)
04:05PM	Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update (Business Wire)
04:30PM	Loading…
Jul-22-26 04:30PM	Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 (Business Wire)
Jun-25-26 09:34AM	Qualcomm upgrade, Intel initiation among today's top calls on Wall Street (The Fly)
Jun-22-26 08:00AM	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer (Business Wire)
Jun-10-26 08:25AM	Exelixis Hits High on Growing Sales, Institutional Inflows (FX Empire)
May-30-26 10:00AM	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 (Business Wire)
May-27-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June (Business Wire)
May-21-26 05:00PM	Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types (Business Wire)
May-19-26 08:00AM	Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer (Business Wire)
May-07-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May (Business Wire) -5.11%
May-05-26 08:17PM	Exelixis, Inc. Q1 2026 Earnings Call Summary (Moby) +9.64%
04:13PM	Exelixis: Q1 Earnings Snapshot (Associated Press)
04:05PM	Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update (Business Wire)
Apr-21-26 04:05PM	Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 (Business Wire) +5.23%
02:20PM	Why Dow Jones Stock Merck Skidded 4% - And Boosted A Key Rival (Investor's Business Daily)
Mar-30-26 07:52AM	Lillys AI commitment expands through deal with Insilico (BioPharma Dive)
09:40AM	Loading…
Mar-02-26 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks) -6.88%
Feb-24-26 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March (Business Wire)
10:58AM	Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge (PR Newswire)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Feb-20-26 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
Feb-18-26 10:50AM	Expand Energy Q4 Earnings Call Highlights (MarketBeat)
Feb-16-26 09:15AM	A Dive into Exelixis (EXEL) International Revenue Trends and Forecasts (Zacks)
Feb-13-26 10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:20AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Feb-12-26 12:40PM	Exelixis Reports Solid Earnings-Are New Highs Back on the Table? (MarketBeat)
11:40AM	EXEL or LQDA: Which Is the Better Value Stock Right Now? (Zacks)
10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-11-26 10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
08:30AM	Exelixis, Inc. Q4 2025 Earnings Call Summary (Moby)
12:01AM	Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-10-26 07:30PM	Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics (Zacks)
07:29PM	Exelixis Q4 Earnings Call Highlights (MarketBeat)
05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:22PM	Exelixis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update (Business Wire)
09:32AM	4 Discounted PEG Value Stocks to Boost Your Portfolio's Health (Zacks)
06:41AM	Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In (Insider Monkey)
Feb-09-26 07:12PM	2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD (Zacks)
11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-05-26 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) (Zacks)
10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-04-26 09:45AM	Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Feb-03-26 10:00AM	Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
09:40AM	Should Value Investors Buy Exelixis (EXEL) Stock? (Zacks)
Feb-02-26 08:00AM	Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer (Business Wire)
Jan-31-26 07:13PM	2 Stocks That Could Soar This Year (Motley Fool)
Jan-28-26 05:42AM	Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies (Pharmaceutical Technology)
Jan-27-26 04:05PM	Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 (Business Wire)
11:40AM	EXEL vs. EXAS: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Jan-20-26 04:59AM	Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch (Insider Monkey)
Jan-15-26 03:01PM	Exelixis, Inc. (EXEL): A Bull Case Theory (Insider Monkey)
09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-14-26 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-12-26 09:33AM	Exelixis Posts Preliminary '25 Results, Issues '26 Outlook (Zacks)
Jan-11-26 04:00PM	Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 (Business Wire)
Jan-09-26 05:18PM	Signet Jewelers, Natural Gas Services, and More Stocks See Action From Activist Investors (Barrons.com)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks)
05:35AM	2 Healthcare Stocks to Buy for 2026 and Beyond (Motley Fool)
Jan-07-26 08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire) +5.75%
Jan-06-26 04:05PM	Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 (Business Wire)
Jan-03-26 07:20AM	Klaviyo, Wingstop among Stephens Best Ideas for 2026 (TipRanks)
Dec-31-25 12:46PM	See How Rare Bullish Inflows Lift Outliers Like Exelixis (FX Empire)
09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
Dec-30-25 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-18-25 02:19PM	Exelixis Near A Buy Point. Relative Strength Rating Climbs. (Investor's Business Daily)
09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Dec-15-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
Dec-04-25 11:30AM	Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-03-25 04:05PM	Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 (Business Wire)
Dec-02-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-01-25 08:06PM	2 Under-the-Radar Stocks to Buy Heading Into 2026 (Motley Fool)
Nov-28-25 09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
Nov-17-25 09:15AM	Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention (Zacks)
Nov-13-25 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Nov-12-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-11-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
Nov-06-25 04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November (Business Wire)
04:56AM	Company News for Nov 6, 2025 (Zacks)

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

PhDMichael M. Morrissey

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beckerle Mary C	Director	Aug 10 '26	Sale	53.66	9,812	526,512	16,079	Aug 12 07:34 PM
MARY BECKERLE	Director	Aug 10 '26	Proposed Sale	53.66	9,812	526,496		Aug 10 04:15 PM
WYSZOMIERSKI JACK L	Director	Jun 01 '26	Sale	50.55	3,925	198,409	284,384	Jun 03 06:52 PM
Eckhardt Sue Gail	Director	Jun 01 '26	Sale	50.14	9,812	491,974	16,079	Jun 03 06:51 PM
Eckhardt Sue Gail	Director	Jun 01 '26	Proposed Sale	50.87	9,812	499,136		Jun 01 04:16 PM
JACK L WYSZOMIERSKI	Director	Jun 01 '26	Proposed Sale	50.55	3,925	198,409		Jun 01 04:04 PM
Aftab Dana	EVP, Research and Development	May 26 '26	Sale	50.35	43,451	2,187,758	594,741	May 28 06:25 PM
DANA T AFTAB	Officer	May 26 '26	Proposed Sale	50.35	43,451	2,187,758		May 26 04:09 PM
Haley Patrick J.	EVP, Commercial	May 20 '26	Sale	49.81	32,110	1,599,399	357,638	May 22 05:01 PM
PATRICK JOSEPH HALEY	Officer	May 20 '26	Proposed Sale	49.81	32,110	1,599,444		May 20 04:31 PM
Senner Christopher J.	EVP and CFO	May 18 '26	Sale	50.00	34,901	1,745,050	952,317	May 19 06:58 PM
Hefti Brenda	SVP and General Counsel	May 18 '26	Sale	50.21	6,625	332,641	106,762	May 19 06:58 PM
CHRISTOPHER J SENNER	Officer	May 18 '26	Proposed Sale	50.00	34,901	1,745,179		May 18 04:49 PM
BRENDA JOY HEFTI	Officer	May 18 '26	Proposed Sale	50.21	6,625	332,641		May 18 04:23 PM
BOMBORA RISE FOUNDATION	Family foundation of the CEO o	May 14 '26	Proposed Sale	50.91	100,000	5,091,190		May 14 04:30 PM
Beckerle Mary C	Director	May 07 '26	Option Exercise	23.24	3,856	89,613	25,236	May 08 07:03 PM
Beckerle Mary C	Director	May 07 '26	Sale	48.45	7,712	373,646	17,524	May 08 07:03 PM
Freire Maria C	Director	May 07 '26	Option Exercise	19.77	20,634	407,934	121,453	May 08 07:03 PM
Freire Maria C	Director	May 07 '26	Sale	46.00	20,634	949,164	100,819	May 08 07:03 PM
POSTE GEORGE	Director	May 07 '26	Sale	45.71	60,000	2,742,600	118,832	May 08 07:03 PM
MARY BECKERLE	Director	May 07 '26	Proposed Sale	48.45	7,712	373,646		May 07 04:39 PM
GEORGE H POSTE	Director	May 07 '26	Proposed Sale	45.71	60,000	2,742,468		May 07 04:36 PM
MARIA C FREIRE	Director	May 07 '26	Proposed Sale	46.00	20,634	949,164		May 07 04:07 PM
Aftab Dana	EVP, Research and Development	Feb 24 '26	Sale	44.50	47,918	2,132,351	616,106	Feb 26 06:41 PM
DANA T AFTAB	Officer	Feb 24 '26	Proposed Sale	44.50	47,918	2,132,351		Feb 24 04:05 PM
Aftab Dana	EVP, Research and Development	Feb 19 '26	Sale	44.35	29,873	1,324,868	664,024	Feb 23 06:50 PM
WYSZOMIERSKI JACK L	Director	Feb 18 '26	Option Exercise	19.77	20,634	407,934	379,516	Feb 20 08:36 PM
WYSZOMIERSKI JACK L	Director	Feb 18 '26	Sale	44.01	99,574	4,382,252	279,942	Feb 20 08:36 PM
Smith Julie	Director	Feb 18 '26	Option Exercise	20.11	64,117	1,289,298	64,677	Feb 19 07:18 PM
Smith Julie	Director	Feb 17 '26	Option Exercise	18.19	42,422	771,656	63,012	Feb 19 07:18 PM
Smith Julie	Director	Feb 18 '26	Sale	44.44	64,117	2,849,200	20,590	Feb 19 07:18 PM
Smith Julie	Director	Feb 17 '26	Sale	43.33	42,422	1,838,145	20,590	Feb 19 07:18 PM
DANA T AFTAB	Officer	Feb 19 '26	Proposed Sale	44.35	29,873	1,324,868		Feb 19 04:06 PM
Senner Christopher J.	EVP and CFO	Feb 13 '26	Sale	43.00	34,278	1,473,954	1,042,579	Feb 18 08:49 PM
Senner Christopher J.	EVP and CFO	Feb 17 '26	Sale	43.67	30,617	1,337,044	976,092	Feb 18 08:49 PM
Haley Patrick J.	EVP, Commercial	Feb 17 '26	Sale	43.52	67,814	2,950,941	381,908	Feb 18 08:49 PM
MORRISSEY MICHAEL	President and CEO	Feb 13 '26	Option Exercise	21.31	494,700	10,542,057	2,319,941	Feb 18 08:49 PM
Eckhardt Sue Gail	Director	Feb 13 '26	Sale	43.79	3,856	168,854	17,524	Feb 18 08:49 PM
Oliver Bob	Director	Feb 13 '26	Option Exercise	19.28	9,088	175,217	51,370	Feb 18 08:48 PM
Oliver Bob	Director	Feb 13 '26	Sale	43.81	30,250	1,325,339	21,120	Feb 18 08:48 PM
Hefti Brenda	SVP and General Counsel	Feb 18 '26	Sale	44.01	18,669	821,623	96,512	Feb 18 08:48 PM
JULIE ANNE SMITH	Director	Feb 18 '26	Proposed Sale	44.44	64,117	2,849,200		Feb 18 05:55 PM
BRENDA JOY HEFTI	Officer	Feb 18 '26	Proposed Sale	44.01	18,669	821,664		Feb 18 04:30 PM
JACK L WYSZOMIERSKI	Director	Feb 18 '26	Proposed Sale	44.01	99,574	4,382,507		Feb 18 04:01 PM
JULIE ANNE SMITH	Director	Feb 17 '26	Proposed Sale	44.33	42,422	1,880,440		Feb 17 06:47 PM
CHRISTOPHER J SENNER	Officer	Feb 17 '26	Proposed Sale	43.67	30,617	1,337,035		Feb 17 06:45 PM
PATRICK JOSEPH HALEY	Officer	Feb 17 '26	Proposed Sale	43.52	67,814	2,951,083		Feb 17 06:43 PM
Eckhardt Sue Gail	Director	Feb 13 '26	Proposed Sale	42.89	3,856	165,384		Feb 13 04:39 PM
CHRISTOPHER J SENNER	Officer	Feb 13 '26	Proposed Sale	43.00	34,278	1,473,964		Feb 13 04:07 PM
ROBERT L OLIVER	Director	Feb 13 '26	Proposed Sale	43.82	30,250	1,325,408		Feb 13 04:07 PM
BOMBORA RISE FOUNDATION	Family foundation of the CEO o	Feb 12 '26	Proposed Sale	43.25	5,000	216,250		Feb 12 07:02 PM
Haley Patrick J.	Officer	Nov 20 '25	Proposed Sale	41.78	10,648	444,873		Dec 12 06:08 PM
JOHNSON DAVID EDWARD	Director	Nov 25 '25	Buy	43.12	27,532	1,187,235	1,553,262	Nov 26 04:05 PM
Haley Patrick J.	EVP, Commercial	Nov 20 '25	Sale	41.88	34,187	1,431,757	0	Nov 24 07:47 PM
Haley Patrick J.	EVP, Commercial	Nov 21 '25	Sale	42.58	28,043	1,194,071	374,029	Nov 24 07:47 PM
Haley Patrick J.	EVP, Commercial	Nov 20 '25	Sale	42.11	10,000	421,100	402,072	Nov 24 07:47 PM
PATRICK JOSEPH HALEY	Officer	Nov 20 '25	Proposed Sale	42.11	10,000	421,052		Nov 20 04:02 PM
PAPADOPOULOS STELIOS	Director	Nov 12 '25	Sale	43.55	100,000	4,355,000	1,189,228	Nov 13 07:12 PM
Aftab Dana	EVP, Research and Development	Nov 11 '25	Sale	42.50	48,383	2,056,278	664,778	Nov 13 07:12 PM
Beckerle Mary C	Director	Nov 11 '25	Option Exercise	23.24	5,784	134,420	46,002	Nov 13 07:12 PM
Beckerle Mary C	Director	Nov 11 '25	Sale	41.93	24,622	1,032,414	21,380	Nov 13 07:12 PM
JEFFREY J HESSEKIEL	Officer	Nov 13 '25	Proposed Sale	43.15	40,000	1,726,128		Nov 13 04:11 PM
Stelios Papadopoulos	Director	Nov 12 '25	Proposed Sale	43.55	100,000	4,355,204		Nov 12 05:41 PM
JEFFREY J HESSEKIEL	Officer	Nov 12 '25	Proposed Sale	43.02	60,000	2,581,006		Nov 12 04:16 PM
DANA T AFTAB	Officer	Nov 11 '25	Proposed Sale	42.50	48,383	2,056,360		Nov 12 10:30 AM
MARY BECKERLE	Director	Nov 11 '25	Proposed Sale	41.93	24,622	1,032,436		Nov 12 09:10 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXEL

Exelixis Inc

Upgrade your Finviz experience